Advertisement

Topics

Latest Biotechnology Products NewsRSS

06:25 EST 20th February 2017 | BioPortfolio

Atara Biotherapeutics Inc ATRA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryAtara Biotherapeutics Inc Atara is a clinicalstage biopharmaceutical company that develops therapies for medical needs. The company develops drugs for muscle wasting conditions and cancer. Its research is based on the ability of myostatin and activin, members of the TGFbeta family of proteins, and other biological targets to change the course of disease progression by being effective in a n...

O'Connor fund owns 9.5% of Protalix Biotherapeutics

Protalix's share price has shot up 300% after plunging following a debt settlement in December.

Global Diabetic Therapeutic Market 20172021 [Updated: 01022017] Prices from USD $3500

About Diabetic TherapeuticThe global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.Technavio's a...

Extrapolation and pharmacovigilance for biosimilars

The issue of extrapolation and pharmacovigilance for biosimilars was discussed in the presentation [1] of Dr Dr Martina Weise, Head of the Licensing Division at the Federal Institute for Drugs and Medical Devices (BfArM), at the 14th Annual Biosimilar Medicines Group Conference.

Regional management of biosimilars in Germany

Biosimilars offer alternative treatment options and reduce the financial burden on healthcare systems often brought about by more expensive originator drugs. Approved biosimilars of tumour necrosis factor-alpha (TNF-α) inhibitors, such as infliximab or etanercept, are managed differently across Europe. A recent study by Dr Mathias Flume assesses the prescription structure and regional uptake of t...

XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering

RAANANA, Israel, February 17, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has entered into definitive agreements with institutional investors to receive gross proceeds of $2.5 million. In connection with the offering,...

ImMAGE Biotherapeutics Closes Out 2016 in France as a YEi Laureate

PHILADELPHIA, Feb. 16, 2017 /PRNewswire-USNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power of the immune system to find a better treatment for triple negative breast cancer (TNBC), announced today their completion of the YEi Start in France program. The YEi Start in France program is an accelerator designed to help entrepreneur...

Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results

BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Thursday, February 23, 2017. Alder management will host a c...

Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017

BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, March 1, 2017 at 8:00 a.m. ET to discuss its fourth quarter and full year 2016 financial results and provide corporate ...

Biosimilar group set to lobby new HHS Secretary to reverse reimbursement policy

Industry group the Biosimilars Forum has welcomed President Trump’s pick of Representative Tom Price as Secretary of Health and Human Services.

GPhA changes name to the Association for Accessible Medicines

Brian BerkIts new identity will improve recognition that the generic and biosimilar medicines industry is one of “the nation's great health care success stories, and that competition from generics and biosimilars lowers the cost of medicine.” read more

Generic and Biosimilar Manufacturers Launch New Brand & Campaign to Expand Access to Medicines

WASHINGTON, Feb. 14, 2017 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association, the nation's largest trade group representing generic pharmaceutical and biosimilar companies, today unveiled a new national effort to contain the cost of prescription medicines. The group is becoming the Association for Accessible Medicines (AAM) to communicate its mission to make more medicines more acce...

Global Biosimilar Market Outlook 2022

LONDON, Feb. 13, 2017 /PRNewswire/ -- A biosimilar is a biologic product that is similar to a regulatory body approved reference product, and has no clinically meaningful differences in terms of safety and effectiveness from that reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. The global biosimilars market is expected to witness a s...

Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders

CARMIEL, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that its board of directors approved the record date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on or about April 10, 2017.  Holders of the Company’s common stock at the close of business on March 15, 2017, the recor...

Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017

Data to be presented in three oral presentations and two poster presentations CARMIEL, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 13th Annual WORLDSymposium™ 2017.  The details are as follows: 13th Annual WORLDSymposium™ 2017 February 13 – 17, 2017 Manchester Grand Hya...

Provenance Biopharmaceuticals Corp Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryProvenance Biopharmaceuticals Corp Provenance is a biopharmaceutical company that focuses on that development novel immunotherapeutics to treat cancer and other serious, lifethreatening diseases. The company offers cancer drugs based on antibodies such as Avastin, Erbitux, Hercepton, and Rituxan. Its DILeu16IL2 is a antibodycytokine fusion protein targeting the B cell antigen, CD20. The com...

Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering

KNOXVILLE, Tenn., Feb. 10, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has extended the expiration date of its rights offering to Friday, March 3, 2017 at 5:00 p.m. Eastern Time. All other terms and conditions of the right...

Biosimilars in 2016: the highlights

Previous years have been momentous for the biosimilars industry and 2016 is no exception [1]. Important milestones achieved during 2016 were the biosimilar approvals of Inflectra (infliximab-dyyb), Erelzi (etanercept-szzs) and Amjevita (adalimumab-atto) by the US Food and Drug Administration (FDA).

EMA approval for adalimumab biosimilars Amgevita and Solymbic

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 27 January 2017 that it had recommended granting of marketing authorization for the adalimumab biosimilars Amgevita and Solymbic.

Tailored and reduced clinical programme for biosimilars

The European Medicines Agency (EMA) is constantly issuing new guidelines and updating its existing guidelines based on new evidence and rapid advances in analytical sciences.  Dr Martina Weise, Head of the Licensing Division at the Federal Institute for Drugs and Medical Devices (BfArM), discussed tailored and reduced clinical programme for biosimilarsin the European Union (EU) in her present...

Position statement on approval of biosimilars in Latin America

The Fifth Latin American Forum on Biosimilars (FLAB) was held in Brasilia, Brazil in 2015 with the theme of ‘Interchangeability and Automatic Substitution’.  Discussions centred on the approval of CT-P13, an infliximab biosimilar; and RTXM83, a proposed rituximab biosimilar, in both Brazil and Argentina. Following these discussions, Babini et al. [1] published a FLAB position statement on...

Pfenex Inc. to Participate in Panel Discussion at 2017 BIO CEO & Investor Conference

SAN DIEGO, Feb. 10, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high-value and difficult to manufacture proteins, today announced that it will participate in the BIO 2017 CEO & Investor Conference in New York City. Pfenex's Interim CEO, Patrick Lucy, is scheduled to participate i...

Vaxil BioTherapeutics To Present At BIO CEO & Investor Conference February 13 - 14, 2017

  Life Sciences Jobs   ...

Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

SAN JOSE, California and OXFORD, England, February 9, 2017 /PRNewswire/ -- Oxford BioTherapeutics ("OBT"), an international biotechnology company developing clinical stage antibody therapeutics for cancer, today announced a significant strengthening of its oncology focused Board of Directors with the appointment of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as a non-...

Alder BioPharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference

BOTHELL, Wash., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Leerink Partners 6th Annual Global Healthcare Conference at 1:00 p.m. ET (10:00 a.m. PT) on Thursday, February 16, 2017 in New York, NY. The ...

Quick Search
Advertisement
 

review and buy Biotechnology Products market research data and corporate reports here